Literature DB >> 23408061

Hypercalcitoninemia in thyroid conditions other than medullary thyroid carcinoma: a comparative analysis of calcium and pentagastrin stimulation of serum calcitonin.

Kerstin Lorenz1, Malik Elwerr, Andreas Machens, Mohammed Abuazab, Hans-Jürgen Holzhausen, Henning Dralle.   

Abstract

PURPOSE: Calcitonin screening aims at uncovering occult medullary thyroid cancer (MTC) in patients with nodular thyroid disease. Elevated basal calcitonin serum levels call for calcitonin stimulation, the level of which may direct the extent of surgery. Because pentagastrin has become restricted, calcium has increasingly been used instead for stimulation. This study identified a new spectrum of patients demonstrating a false-positive hypercalcitoninemia in the absence of C-cell disease, carrying multinodular goiter (MNG), thyroiditis, and non-MTC thyroid malignancy, and endeavored to explore the feasibility of extrapolating pentagastrin-stimulated to calcium-stimulated calcitonin thresholds.
METHODS: Altogether, 43 (9.5 %) of 455 patients with nodular thyroid disease revealed increased basal calcitonin serum levels between 2005 and 2012, for which they underwent intravenous stimulation with pentagastrin (31 patients) or calcium gluconate (12 patients) before and after primary thyroidectomy.
RESULTS: Stimulation with calcium gluconate resulted in significantly higher and more variable preoperative calcitonin serum levels after 2 (241.2 vs. 104.9 pg/mL; P = 0.018) and 5 min (240.6 vs. 87.4 pg/mL; P = 0.007) than stimulation with pentagastrin. Stimulation with calcium gluconate produced 10-fold (nodular goiter), 15-fold (thyroiditis), and 21-fold (thyroid neoplasia other than MTC) calcitonin increases over baseline, as opposed to 5-fold, 10-fold, and 8-fold increases after stimulation with pentagastrin. None of the 43 patients, all of whom reverted to undetectable calcitonin serum levels after thyroidectomy, had immunohistochemical evidence of C-cell disease. Subgroup analyses according to gender and thyroid disease, being limited by the low number of patients in each subgroup, did not yield significant differences.
CONCLUSIONS: Calcium stimulation yields significantly greater calcitonin levels than pentagastrin stimulation, precluding generalization of pentagastrin-stimulated to calcium-stimulated calcitonin thresholds. After calcium stimulation, false-positive findings appear to be more common in patients of female gender and patients with thyroiditis and thyroid neoplasia other than MTC, potentially effecting surgical overtreatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23408061     DOI: 10.1007/s00423-013-1049-6

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  27 in total

1.  Increased calcitonin level in thyroid nodules without medullary carcinoma.

Authors:  H Gibelin; D Essique; C Jones; P Levillain; R Maréchaud; J-L Kraimps
Journal:  Br J Surg       Date:  2005-05       Impact factor: 6.939

2.  Alcohol-stimulated calcitonin release in medullary carcinoma of the thyroid.

Authors:  S L Cohen; I MacIntyre; D Grahame-Smith; J G Walker
Journal:  Lancet       Date:  1973-11-24       Impact factor: 79.321

3.  A short calcium infusion in the diagnosis of medullary thyroid carcinoma.

Authors:  J G Parthemore; D Bronzert; G Roberts; L J Deftos
Journal:  J Clin Endocrinol Metab       Date:  1974-07       Impact factor: 5.958

4.  Serum calcitonin levels with calcium loading tests before and after total thyroidectomy in patients with thyroid diseases other than medullary thyroid carcinoma.

Authors:  Takumi Kudo; Akira Miyauchi; Yasuhiro Ito; Tomonori Yabuta; Hiroyuki Inoue; Takuya Higashiyama; Chisato Tomoda; Mitsuhide Hirokawa; Nobuyuki Amino
Journal:  Endocr J       Date:  2011-02-24       Impact factor: 2.349

5.  Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders.

Authors:  H Vierhapper; B Niederle; C Bieglmayer; K Kaserer; S Baumgartner-Parzer
Journal:  Thyroid       Date:  2005-11       Impact factor: 6.568

Review 6.  Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.

Authors:  Thomas M Behr; Martin P Béhé
Journal:  Semin Nucl Med       Date:  2002-04       Impact factor: 4.446

7.  Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer.

Authors:  Carla Colombo; Uberta Verga; Caterina Mian; Stefano Ferrero; Michela Perrino; Leonardo Vicentini; Davide Dazzi; Giuseppe Opocher; Maria Rosa Pelizzo; Paolo Beck-Peccoz; Laura Fugazzola
Journal:  J Clin Endocrinol Metab       Date:  2011-12-14       Impact factor: 5.958

8.  Thyrocalcitonin: stimulation of secretion by pentagastrin.

Authors:  C W Cooper; W H Schwesinger; A M Mahgoub; D A Ontjes
Journal:  Science       Date:  1971-06-18       Impact factor: 47.728

9.  Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer.

Authors:  Andreas Machens; Florian Hoffmann; Carsten Sekulla; Henning Dralle
Journal:  Endocr Relat Cancer       Date:  2009-09-02       Impact factor: 5.678

10.  The role of prophylactic central neck dissection in differentiated thyroid carcinoma: issues and controversies.

Authors:  Kai-Pun Wong; Brian Hung-Hin Lang
Journal:  J Oncol       Date:  2011-09-29       Impact factor: 4.375

View more
  4 in total

Review 1.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

2.  Serum calcitonin reference values for calcium stimulation tests by electrochemiluminescence immunoassay in Japanese men with non-medullary thyroid carcinoma.

Authors:  Minoru Kihara; Akira Miyauchi; Takumi Kudo; Mitsuyoshi Hirokawa; Akihiro Miya
Journal:  Surg Today       Date:  2017-08-18       Impact factor: 2.549

Review 3.  Biochemical Testing in Thyroid Disorders.

Authors:  Nazanene H Esfandiari; Maria Papaleontiou
Journal:  Endocrinol Metab Clin North Am       Date:  2017-06-08       Impact factor: 4.741

Review 4.  Laryngeal Neuroendocrine Tumor With Elevated Serum Calcitonin: A Diagnostic and Therapeutic Challenge. Case Report and Review of Literature.

Authors:  Tiziana Feola; Giulia Puliani; Franz Sesti; Roberta Modica; Marco Biffoni; Cira Di Gioia; Raffaella Carletti; Emanuela Anastasi; Valentina Di Vito; Roberta Centello; Andrea Lenzi; Andrea M Isidori; Antongiulio Faggiano; Elisa Giannetta
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-16       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.